BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 33992189)

  • 1. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
    Anamnart C; Kitjarak R
    J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
    Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
    Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
    Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
    Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
    Kocer B; Guven H; Comoglu SS
    Biomed Res Int; 2016; 2016():7563705. PubMed ID: 27493964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.
    Nevrly M; Kanovsky P; Vranova H; Langova K; Hlustik P
    Neurol Sci; 2010 Oct; 31(5):565-9. PubMed ID: 20464572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
    Postuma RB; Espay AJ; Zadikoff C; Suchowersky O; Martin WR; Lafontaine AL; Ranawaya R; Camicioli R; Lang AE
    Neurology; 2006 Jun; 66(12):1941-3. PubMed ID: 16801668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
    Zhao P; Yang JF; Liu W; Wang Y; Sun YN; Li Q; Zhang W; Zhang BS
    Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(7):512-5. PubMed ID: 23660319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.
    Triantafyllou NI; Kararizou E; Angelopoulos E; Tsounis S; Boufidou F; Evangelopoulos ME; Nikolaou C; Vassilopoulos D
    Eur Neurol; 2007; 58(2):96-9. PubMed ID: 17565222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients.
    Gorgone G; Currò M; Ferlazzo N; Parisi G; Parnetti L; Belcastro V; Tambasco N; Rossi A; Pisani F; Calabresi P; Ientile R; Caccamo D
    Neuromolecular Med; 2012 Mar; 14(1):84-90. PubMed ID: 22354693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease: Research puts spotlight on thiamine deficiency and cardiovascular health.
    Finsterer J; Scorza CA; de Almeida AG; Rodrigues AM; Scorza FA
    J Clin Neurosci; 2021 Nov; 93():270-271. PubMed ID: 34167881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.
    Zesiewicz TA; Wecker L; Sullivan KL; Merlin LR; Hauser RA
    Clin Neuropharmacol; 2006; 29(3):106-11. PubMed ID: 16772808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
    Di Rocco A; Werner P
    Neurology; 2007 Apr; 68(17):1440; author reply 1440-1. PubMed ID: 17452598
    [No Abstract]   [Full Text] [Related]  

  • 13. Homocysteine in restless legs syndrome.
    Bachmann CG; Guth N; Helmschmied K; Armstrong VW; Paulus W; Happe S
    Sleep Med; 2008 May; 9(4):388-92. PubMed ID: 17900981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
    Lamberti P; Zoccolella S; Armenise E; Lamberti SV; Fraddosio A; de Mari M; Iliceto G; Livrea P
    Eur J Neurol; 2005 May; 12(5):365-8. PubMed ID: 15804266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.
    Nevrly M; Kanovsky P; Vranova H; Langova K; Hlustik P
    Parkinsonism Relat Disord; 2009 Jul; 15(6):477-8. PubMed ID: 19028438
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma homocysteine, folate and vitamin B12 levels in Parkinson's disease in China: A meta-analysis.
    Dong B; Wu R
    Clin Neurol Neurosurg; 2020 Jan; 188():105587. PubMed ID: 31733593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis.
    Xie Y; Feng H; Peng S; Xiao J; Zhang J
    Neurosci Lett; 2017 Jan; 636():190-195. PubMed ID: 27840145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease.
    Rogers JD; Sanchez-Saffon A; Frol AB; Diaz-Arrastia R
    Arch Neurol; 2003 Jan; 60(1):59-64. PubMed ID: 12533089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
    Camicioli RM; Bouchard TP; Somerville MJ
    Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
    Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
    Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.